Viridian Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -2.43%
- Market cap
- $3.46B
- 113.56M shares
- Filings
- 821
Q3 2026+23,359.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2024N/M FY23 yoy
Q3 2026+113.2% FY25 yoy
- $3.46B
- —
- 131.6×
- 6.0×
- -9.92%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $70,849,000 | reported | |
| FY 2024 | 2024-12-31 | $302,000 | reported | |
| FY 2023 | 2023-12-31 | $314,000 | reported | |
| FY 2022 | 2022-12-31 | $1,772,000 | reported | |
| FY 2021 | 2021-12-31 | $2,963,000 | reported | |
| FY 2020 | 2020-12-31 | $1,050,000 | reported | |
| FY 2019 | 2019-12-31 | $4,461,000 | reported | |
| FY 2018 | 2018-12-31 | $8,386,000 | reported | |
| FY 2017 | 2017-12-31 | $4,003,000 | reported | |
| FY 2016 | 2016-12-31 | $3,477,000 revised | reported | |
| FY 2015 | 2015-12-31 | $5,706,000 revised | reported | |
| FY 2014 | 2014-12-31 | $6,484,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2016 | — | $2.00K | $2.00K | — | 21.37M sh | +99.6% | — |
Segments
Products
LineFY2025ShareChange
License$70.00M99%—
Collaboration$849.00K1.2%+181.1%
Collaboration Revenue———
Collaboration revenue———
Grant revenue———
Reimbursement Revenue———
Total$70.85M
Pharmaceutical preparations
Viridian Therapeutics, Inc. is the 115th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
CTMXCytomX Therapeutics, Inc.$76.2M44.8%22.8%$442.5MABCLAbCellera Biologics Inc.$75.1M160.6%194.9%$3.8BBCYCBicycle Therapeutics PLC$72.6M105.8%301.7%$241.1MASMBAssembly Biosciences, Inc.$72.3M153.5%8.5%$431.6M
VRDNViridian Therapeutics, Inc. (this company)$70.8M23,359.9%483.6%$3.5B
RMTIRockwell Medical, Inc.$69.3M31.8%7.7%$29.6MKURAKura Oncology, Inc.$67.5M25.2%412.9%$682.7MENTAEnanta Pharmaceuticals Inc$65.3M3.4%125.4%$325.8MFBIOFortress Biotech, Inc.$63.3M9.7%10.8%$66.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR